Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma
Jesús San Miguel
Frontline treatment of elderly multiple myeloma patients and management of relapse/refractory
Enrique Ocio et al.
Isatuximab for multiple myeloma - promising results and next steps
The differences between biological and chronological age, with their implications on AML treatment
Improving the assessment of response in relapsed MM